PUBLISHER: The Business Research Company | PRODUCT CODE: 1945234
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945234
Genomic and proteomic tools comprise advanced methods and technologies used to investigate the complete set of genes (genome) and proteins (proteome) in an organism. Genomic tools analyze DNA and RNA to explore gene sequences, expression patterns, mutations, and interactions, utilizing techniques such as DNA sequencing, PCR, microarrays, and genome editing. Proteomic tools focus on protein structure, function, abundance, and interactions through methods including mass spectrometry, 2D gel electrophoresis, and protein microarrays.
The primary product categories of genomic and proteomic tools include instruments, consumables, software, and services. Instruments are specialized devices designed to measure, detect, separate, or manipulate physical or molecular properties in laboratory samples, allowing precise observation and control beyond human capabilities, covering areas from microscopy to analytical measurement. The technologies involved include sequencing, microarrays, polymerase chain reaction (PCR), and chromatography, which operate through stages of sample preparation, library preparation, data analysis, and reporting. Applications extend to drug discovery, diagnostics, personalized medicine, agriculture, and animal research.
Tariffs are impacting the genomic and proteomic tool market by increasing costs of imported instruments, reagents, and precision components, particularly impacting sequencing and mass spectrometry segments. North America and Europe face supply pressures due to reliance on Asia-Pacific manufacturing hubs. Higher prices have slowed adoption in cost-sensitive research institutions. However, tariffs are encouraging local manufacturing, regional supplier development, and innovation in cost-efficient genomic and proteomic solutions.
The genomic and proteomic tool market research report is one of a series of new reports from The Business Research Company that provides genomic and proteomic tool market statistics, including genomic and proteomic tool industry global market size, regional shares, competitors with a genomic and proteomic tool market share, detailed genomic and proteomic tool market segments, market trends and opportunities, and any further data you may need to thrive in the genomic and proteomic tool industry. This genomic and proteomic tool market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The genomic and proteomic tool market size has grown rapidly in recent years. It will grow from $33.14 billion in 2025 to $37 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to rising genomic research funding, expansion of NGS technologies, growth in pharmaceutical R&D, increasing academic research activities, declining sequencing costs.
The genomic and proteomic tool market size is expected to see rapid growth in the next few years. It will grow to $56.95 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growth of precision medicine, increasing clinical genomics adoption, rising demand for proteomics in drug discovery, expansion of personalized diagnostics, advancements in bioinformatics tools. Major trends in the forecast period include high-throughput sequencing adoption, integrated multi-omics platforms, automation in sample preparation, growth of cloud-based bioinformatics, expansion of biomarker discovery.
The rising adoption of personalized medicine is expected to drive the growth of the genomic and proteomic tool market in the coming years. Personalized medicine customizes prevention, diagnosis, and treatment based on an individual's molecular profile using biomarkers from DNA, RNA, and proteins. This trend is fueled by advances in genomics, proteomics, and biomarker discovery, which enable tailored treatments, targeted therapies, improved diagnostics, and precision healthcare solutions. Genomic and proteomic tools are essential in this process, as they identify genetic variations and protein biomarkers, helping clinicians optimize treatments and enhance patient outcomes. For instance, in February 2024, the Personalized Medicine Coalition reported that the USFDA approved 16 new personalized treatments for rare disease patients in 2023, up from six in 2022, highlighting the increasing adoption of personalized medicine and its role in driving the genomic and proteomic tool market.
Companies in the genomic and proteomic tools market are increasingly investing in spatial multi-omics technologies, which allow for the in-situ detection of RNA and proteins within the same cell, thereby integrating molecular data layers and preserving tissue architecture. This approach, known as spatial multi-omics, enables the measurement of gene expression and protein markers at single-cell or subcellular resolution, providing deeper biological insights than traditional single-modality tests. For instance, in August 2025, 10x Genomics, a US-based biotech company, launched Xenium Protein, a groundbreaking assay for single-cell RNA and protein analysis on the Xenium in situ platform. This solution simplifies workflows by eliminating the need for cross-platform data integration and comes with pre-validated protein subpanels for easier setup and quality control. These innovations enhance the ability to maintain spatial context while expanding biomarker panels for applications such as target validation, patient stratification, and mechanism-of-action studies.
In July 2024, Thermo Fisher Scientific Inc., a US-based biotech company, acquired Olink Holding AB to bolster its proteomics portfolio. This acquisition integrates Olink's proximity extension assay (PEA) platform into Thermo Fisher's Life Sciences Solutions segment, strengthening its capabilities in high-plex protein biomarker discovery and quantification. This acquisition complements Thermo Fisher's existing mass spectrometry and sequencing technologies and accelerates progress in translational research and the development of companion diagnostics. Olink Holding AB, a company based in Sweden, is known for its next-generation proteomics tools and solutions.
Major companies operating in the genomic and proteomic tool market are F. HoffmannLa Roche, Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, GE Healthcare, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., Bruker Corporation, Waters Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., PerkinElmer Inc., Promega, Novogene Corp., Oxford Nanopore Technologies Ltd., Pacific Biosciences of California Inc., Sophia Genetics, LC Sciences
North America was the largest region in the genomic and proteomic tool market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genomic and proteomic tool market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the genomic and proteomic tool market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The genomic and proteomic tool market consists of revenues earned by entities by providing services such as DNA sequencing systems, gene expression analysis platforms, microarray technologies, and mass spectrometry systems. The market value includes the value of related goods sold by the service provider or included within the service offering. The genomic and proteomic tools market also includes sales of electrophoresis equipment, and chromatography instruments. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Genomic And Proteomic Tool Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses genomic and proteomic tool market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for genomic and proteomic tool ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The genomic and proteomic tool market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.